Insulin resistance and the endothelium

被引：40

作者：

Quiñones M.J. ^{[1
]}

Nicholas S.B. ^{[1
]}

Lyon C.J. ^{[1
]}

机构：

[1] David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, CA 90095

来源：

Current Diabetes Reports | 2005年 / 5卷 / 4期

关键词：

Simvastatin; Endothelial Dysfunction; Endothelial Function; Rosiglitazone; Myocardial Blood Flow;

D O I：

10.1007/s11892-005-0018-z

中图分类号：

学科分类号：

摘要：

Type 2 diabetes is a cardiovascular disease equivalent that is associated with accelerated atherosclerosis and significant mortality. However, the metabolic syndrome and prediabetes are associated with increased cardiovascular mortality, indicating that atherogenic vascular changes begin prior to the onset of overt diabetes. At the core of diabetes and the metabolic syndrome is insulin resistance (IR), which sets the stage for dyslipidemia, hypertension, and inflammation. Endothelial dysfunction is the first stage of the atherosclerosis process and results from exposure to cardiovascular risk factors, such as IR and diabetes. IR and atherosclerosis follow parallel paths as they progress in severity. Thiazolidinediones, angiotensin-converting enzyme inhibitors, angiotensin receptor-AT I blockers, and statins are widely used in the treatment of diabetes. Emerging evidence indicates that these pharmacologic agents have added mechanisms of action, especially on the endothelium and in the prevention of diabetes. Copyright © 2005 by Current Science Inc.

引用

页码：246 / 253

页数：7

共 69 条

[51]

Cooke J.P., Does ADMA cause endothelial dysfunction?, Arterioscler. Thromb. Vasc. Biol., 20, pp. 2032-2037, (2000)

[52]

Prisant L.M., Preventing type II diabetes mellitus, J. Clin. Pharmacol., 44, pp. 406-413, (2004)

[53]

Scheen A.J., Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials, Diabetes Metab., 30, pp. 487-496, (2004)

[54]

Yusuf S., Pfeffer M.A., Swedberg K., Et al., Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial, Lancet, 362, pp. 777-781, (2003)

[55]

Julius S., Kjeldsen S.E., Weber M., Et al., Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial, Lancet, 363, pp. 2022-2031, (2004)

[56]

Schupp M., Janke J., Clasen R., Et al., Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-{gamma} activity, Circulation, 109, pp. 2054-2057, (2004)

[57]

Benson S.C., Pershadsingh H.A., Ho C.I., Et al., Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR {gamma}-modulating activity, Hypertension, 43, pp. 993-1002, (2004)

[58]

Henriksen E.J., Jacob S., Kinnick T.R., Et al., Selective angiotensin II receptor antagonism reduces insulin resistance in obese zucker rats, Hypertension, 38, pp. 884-890, (2001)

[59]

Quinones M.J., Schindler T., Bulnes-Enriquez I., Et al., Angiotensin receptor blockade with valsartan normalizes coronary endothelial function in prediabetic subjects, Circulation, 110, pp. 111-180, (2004)

[60]

Halcox J.P.J., Deanfield J.E., Beyond the laboratory: Clinical implications for statin pleiotropy, Circulation, 109, pp. 1142-1148, (2004)

← 1 2 3 4 5 6 7 →